Please upgrade your browser.
Your participation in this research project can help ensure that the company’s brochure and other materials are relevant to patients
In appreciation of your time and valuable contribution, you will receive an honorarium of $150 payable upon successful completion of the telephone interview.
Tumor ablation is a treatment that destroys cancerous tumors without removing them. This is done using a probe that utilizes thermal energy to heat or cool tumorigenic tissue to cytotoxic levels. Techniques such as computed tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI) are used to guide and position the needle probe into the tumor. Tumor ablative techniques are used in patients having few tumors which are small in size.
Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.
All the news in one place! View the abstracts from the 2017 Genitourinary Cancers Symposium held recently in Orlando, Florida USA.
World Kidney Day promotes education about the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option. Obesity is also a risk factor, along with smoking and others, that may contribute to the development of renal cancers.
In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.
Yes, how tall or short you are decides a few health issues you may experience in your lifetime, says a study. Read on to know more…
The donation will support the research of W. Marston Linehan, M.D., Chief of Urologic Surgery and the Urologic Oncology Branch, Center for Cancer Research, at the National Cancer Institute...
Howard L Kaufman discusses the continuing role of high dose interleukin (HD IL-2), an approved therapy for the treatment of metastatic renal cell carcinoma (mRCC)...
Argos Therapeutics Inc. (ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today that it has entered into a strategic research agreement with Personalis, Inc., a precision medicine company, focused on genomics solutions for immuno-oncology, cancer, and genetic disease.
|Powered by NeonCRM|